Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Clinical-Grade Assay Documentation for German and Global Regulatory Submissions

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Clinical-Grade Assay Documentation for German and Global Regulatory Submissions

CELL & GENE | RNA | BIOLOGICS

A senior scientist with grey hair is mentoring a diverse group of younger scientists or students in a laboratory setting.

Proven Intelligence in Regulatory-Compliant Assay Development.

Executive Summary

This framework outlines the creation of robust, phase-appropriate protocols and training materials for clinical-grade bioanalytical assays. It is designed to satisfy German (PEI/EMA) and harmonized ICH guidelines, producing a single, cohesive documentation package that supports Investigational Medicinal Product Dossier (IMPD) submissions and accelerates timelines by minimizing regulatory friction.

A senior scientist leads a discussion with a group of diverse junior scientists in a bright, modern laboratory setting.

Frequently Asked Questions

How do you ensure assay documentation meets the specific requirements of German regulatory bodies like the Paul-Ehrlich-Institut (PEI)?

Our approach is built on harmonized ICH principles, which form the basis for EMA and PEI requirements. We develop a core documentation package that is fundamentally compliant with GxP standards and then append specific regional requirements, ensuring the data and protocols are presented in the expected format for an IMPD submission without requiring duplicative work.

What is the process for developing training protocols for novel, non-compendial assays?

For novel assays, such as those measuring unique biomarkers, we implement a rigorous development and qualification process. The training protocol is built in parallel, documenting every step, reagent, and instrument parameter. This ensures the method is transferable, reproducible, and can be consistently executed by technical staff across different sites or during tech transfer.

How does robust documentation for clinical-grade assay development impact overall IND timelines?

Comprehensive and clear documentation directly accelerates the path to IND. It provides regulators with a transparent view of an assay’s performance, validity, and control, reducing the likelihood of queries or requests for additional validation data. This proactive approach is a key component of achieving an 18-24 month IND timeline.

A close-up shot of a scientist in a lab coat and blue gloves using a micropipette to transfer a liquid sample into a small test tube.

Phase-Appropriate Documentation for Global Submissions

A unified documentation strategy is a foundational component of a de-risked clinical development plan. For sponsors targeting both European and US markets, creating siloed documentation packages is inefficient and introduces risk. We establish a GxP-compliant framework from the beginning, ensuring that protocols for immunogenicity, potency, and biodistribution assays are written to satisfy the most stringent requirements of global regulators.

This approach ensures that as a program advances, the documentation evolves with it, moving from research-grade to fully qualified and validated methods without fundamental changes to the core protocol structure.

Harmonizing Assay Protocols for the EMA and FDA

While regional differences exist, the foundational principles of good assay development and validation are codified in ICH guidelines. Our process focuses on these harmonized standards to build a universal data package.

  • Unified Protocol Templates: We utilize templates that incorporate fields and specifications required by both the EMA and FDA, preventing the need to redraft entire documents for different submissions.

  • Cross-Referenced Validation Reports: A single, comprehensive validation report is generated that explicitly states compliance with relevant ICH, EMA, and FDA guidance documents.

  • Global Training Standards: Technician training records and protocols are standardized, demonstrating consistent execution regardless of the physical laboratory location. Our >100,000 sq ft facility provides the GxP environment for this work.

Supporting Novel Science with Defensible Documentation

The introduction of novel biomarkers or complex potency assays requires a documentation approach that can clearly articulate the method’s scientific rationale and performance. The regulatory history of early next-generation therapeutics demonstrates that clear, prospective documentation is a significant factor in successful market authorization (PMID: 23808604). Without it, even sound science can face significant delays.

For instance, developing an assay to measure a novel biomarker in cerebrospinal fluid requires meticulous documentation of sample handling, analytical sensitivity, and specificity to be accepted by regulators (PMID: 28934395). The protocol must be robust enough to prove the biomarker’s utility in a clinical context.

This level of detail is built into our documentation and training programs. This expertise has contributed to a 100% successful IND rate since 2019, a track record established by our founding leadership and principal scientists prior to the formal launch of Franklin Biolabs in 2024. This history, which includes a collaboration with leading industry partners, provides the foundation for navigating complex regulatory submissions for our clients.

For more information on our analytical capabilities, please see our parent hub page: Vector | CMC | Analytics Services.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities